NLRP3 and Alzheimer disease: Furthermore, researchers are exploring new targets for anti-inflammatory therapies, such as NLRP3 inflammasomes, as NLRP3 has been linked to the generation of pro-inflammatory cytokines in AD, and anti-inflammatory drugs such as Janus kinase (JAK) inhibitors, which are being tested in clinical trials [68, 104].